Should patients with papillary microcarcinoma undergo radioiodine ablation?

Endocrine

Volumn 44, Issue 2, 2013, Pages 278-279

  Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ABLATION THERAPY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EDITORIAL; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA;

CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; THYROID NEOPLASMS;

EID: 84885631117     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0010-3     Document Type: Editorial

References (15)

1. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009)
2. R. Gallicchio, S. Giacomobono, D. Capacchione, A. Nardelli, F. Barbato, Nappia, T. Pellegrino, G. Storto, Should patients with remnants from thyroid microcarcinoma really not be treated with Iodine-131 ablation? Endocrine 30(2), 506 (2013)
3. P. Malandrino, G. Pellegriti, M. Attard, M.A. Violi, C. Giordano, L. Sciacca, C. Regalbuto, S. Squatrito, R. Vigneri, Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J. Clin. Endocrinol. Metab. 98, 1427-1434 (2013)
4. K.J. Lee, Y.J. Cho, S.J. Kim, S.C. Lee, J.G. Kim, C.J. Ahn, D.H. Lee, Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J. Surg. 35, 318-323 (2011)
5. R.M. Tuttle, G. Rondeau, N.Y. Lee, A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control 18, 89-95 (2011)
6. M.G. Castagna, F. Maino, C. Cipri, Belardini V. Theodoropoulou, A. Cevenini, G. Pacini F, Delayed risk stratification to include the response to initial treatment (surgery and radioiodine ablation) has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165, 441-446 (2011)
7. T.Y. Kim, S.J. Hong, J.M. Kim, W.G. Kim, G. Gong, J.S. Ryu, W.B. Kim, S.-C. Yun, Y.K. Shong, Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer 8, 296 (2008). doi: 10.11186/1471-2407-8-296
8. L. Zhang, W.-J. Wei, Q.-H. Ji, Y.-X. Zhu, Z.-Y. Wang, C.-P. Huang, J.Q. Shen, D.-S. Li, Y. Wu, Risk factors for neck lymph node metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J. Clin. Endocrinol. Metab. 97, 1250-1257 (2012)
9. F. Pacini, Management of papillary microcarcinoma: primum non nocere! J. Clin. Endocrinol. Metab. 98, 1391-1393 (2013)
10. L. Wartofsky, Management of papillary microcarcinoma: primum non nocere? J. Clin. Endocrinol. Metab. 97, 1169-1172 (2012)
11. L.A. Niemeier, A.H. Kuffner, C. Song, S.E. Carty, S.P. Hodak, L. Yip, R.L. Ferris, G.C. Tseng, R.R. Seethala, S.O. Lebeau, M.T. Stang, C. Coyne, J.T. Johnson, A.F. Stewart, Y.E. Nikiforov, A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118, 2069-2077 (2011)
12. M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, B. Bendlova, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O'Neill, M.S. Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R.P. Tufano, S.I. Pai, M.A. Zeiger, W.H. Westra, D.P. Clark, R. Clifton-Bligh, D. Sidransky, P.W. Ladenson, V. Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309(14), 1493-1501 (2013)
13. R. Elisei, D. Viola, L. Torregrossa, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, The BRAF V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J. Clin. Endocrinol. Metab. 97, 4390-4398 (2012)
14. S.T. Lee, S.W. Kim, C.S. Ki, J.H. Jang, J.H. Shin, Y.L. Oh, J.W. Kim, J.H. Chung, Clinical implications of highly sensitive detection of the BRAF V600E mutation in fine needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J. Clin. Endocrinol. Metab. 97, 2299-2306 (2012)
15. G. Gandolfi, V. Sancisi, F. Torricelli, M. Ragazzi, A. Frasoldati, S. Piana, A. Ciarrocchi, Allele percentage of the BRAF V600E mutation in papillary thyroid carcinoma and corresponding lymph node metastases: no evidence for a role in tumor progression. J. Clin. Endocrinol. Metab. 98, E934-E942 (2013)